SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-010995
Filing Date
2019-11-14
Accepted
2019-11-14 09:15:32
Documents
57
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20190930x10q.htm 10-Q 1680791
2 EX-31.1 btai-20190930ex311292755.htm EX-31.1 22050
3 EX-31.2 btai-20190930ex31218a870.htm EX-31.2 21721
4 EX-32.1 btai-20190930ex321e22be3.htm EX-32.1 12378
5 EX-32.2 btai-20190930ex32226d33a.htm EX-32.2 10785
  Complete submission text file 0001558370-19-010995.txt   4272170

Data Files

Seq Description Document Type Size
6 EX-101.INS btai-20190930.xml EX-101.INS 532223
7 EX-101.SCH btai-20190930.xsd EX-101.SCH 34785
8 EX-101.CAL btai-20190930_cal.xml EX-101.CAL 32608
9 EX-101.DEF btai-20190930_def.xml EX-101.DEF 94954
10 EX-101.LAB btai-20190930_lab.xml EX-101.LAB 301416
11 EX-101.PRE btai-20190930_pre.xml EX-101.PRE 224906
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 191216800
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences